← back to search

Maria Serena Longhi

Beth Israel Deaconess Medical Center · US
Area of research
Hepatology · Immunology
Research interest
Research interests include Liver Diseases and Immunity, Adenosine and Purinergic Signaling, Immune Cell Function and Interaction, and Liver Disease Diagnosis and Treatment.
h-index
49
citations
8,022
works
251
NIH funding
primary concept
email

Recent publications

Multi-scaled transcriptomics of chronically inflamed nasal epithelium reveals immune-epithelial dynamics and tissue remodeling in nasal polyp formation
Immunity 2025cited by 7position: middledoi
B and T cells: (Still) the dominant orchestrators in autoimmune hepatitis
Autoimmunity Reviews 2024cited by 14position: firstdoi
Adenosine-mediated immune responses in inflammatory bowel disease
Frontiers in Cell and Developmental Biology 2024cited by 7position: lastdoi
Silencing of aryl hydrocarbon receptor repressor restrains Th17 cell immunity in autoimmune hepatitis
Journal of Autoimmunity 2023cited by 17position: lastdoi
Delivery of therapeutic carbon monoxide by gas-entrapping materials
Science Translational Medicine 2022cited by 80position: middledoi
Extracellular mitochondria drive CD8 T cell dysfunction in trauma by upregulating CD39
Thorax 2022cited by 19position: middledoi
Regulatory T cells in autoimmune hepatitis: an updated overview
Journal of Autoimmunity 2021cited by 84position: firstdoi
Human Leukocyte Antigen Profile Predicts Severity of Autoimmune Liver Disease in Children of European Ancestry
Hepatology 2021cited by 45position: middledoi
Aberrant hepatic trafficking of gut‐derived T cells is not specific to primary sclerosing cholangitis
Hepatology 2021cited by 44position: middledoi
Altered aryl-hydrocarbon-receptor signalling affects regulatory and effector cell immunity in autoimmune hepatitis
Journal of Hepatology 2020cited by 61position: lastdoi
P2X7 receptor activation increases expression of caveolin-1 and formation of macrophage lipid rafts, thereby boosting CD39 activity
Journal of Cell Science 2020cited by 30position: middledoi
Eosinophils and Purinergic Signaling in Health and Disease
Frontiers in Immunology 2020cited by 26position: middledoi
Selective deletion of ENTPD1/CD39 in macrophages exacerbates biliary fibrosis in a mouse model of sclerosing cholangitis
Purinergic Signalling 2019cited by 25position: middledoi
The metabolite BH4 controls T cell proliferation in autoimmunity and cancer
Nature 2018cited by 286position: middledoi
HIF-1α-induced xenobiotic transporters promote Th17 responses in Crohn's disease
Journal of Autoimmunity 2018cited by 52position: lastdoi
The ectonucleotidases <scp>CD</scp>39 and <scp>CD</scp>73: Novel checkpoint inhibitor targets
Immunological Reviews 2017cited by 877position: middledoi
CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury
Journal of Hepatology 2017cited by 186position: middledoi
Regulatory T‐cell conditioning endows activated effector T cells with suppressor function in autoimmune hepatitis/autoimmune sclerosing cholangitis
Hepatology 2017cited by 44position: lastdoi
CD39 mediated regulation of Th17-cell effector function is impaired in juvenile autoimmune liver disease
Journal of Autoimmunity 2016cited by 51position: lastdoi
Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration
Blood 2016cited by 39position: middledoi
In autoimmune hepatitis type 1 or the autoimmune hepatitis–sclerosing cholangitis variant defective regulatory T‐cell responsiveness to IL‐2 results in low IL‐10 production and impaired suppression
Hepatology 2015cited by 103position: lastdoi
Regulatory T cells: Mechanisms of suppression and impairment in autoimmune liver disease
IUBMB Life 2015cited by 72position: middledoi
Regulatory T-cells in autoimmune diseases: Challenges, controversies and—yet—unanswered questions
Autoimmunity Reviews 2014cited by 285position: lastdoi
Alginate Microencapsulated Hepatocytes Optimised for Transplantation in Acute Liver Failure
PLoS ONE 2014cited by 127position: middledoi
Diagnostic criteria of autoimmune hepatitis
Autoimmunity Reviews 2014cited by 108position: middledoi
Characterization of Human CD39+ Th17 Cells with Suppressor Activity and Modulation in Inflammatory Bowel Disease
PLoS ONE 2014cited by 71position: firstdoi
Dysfunctional CD39POS regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis
Hepatology 2013cited by 186position: lastdoi
Biological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states
Journal of Molecular Medicine 2013cited by 78position: firstdoi
The interplay between regulatory and effector T cells in autoimmune hepatitis: Implications for innovative treatment strategies
Journal of Autoimmunity 2013cited by 49position: lastdoi
The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9/tim-3 pathway
Hepatology 2012cited by 146position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Diego Vergani · King's College London15 papers (2012–2024)Giorgina Mieli‐Vergani · King's College London15 papers (2012–2024)Simon C. Robson · Harvard University14 papers (2012–2023)Yun Ma · King's College London12 papers (2012–2023)Rodrigo Liberal · Hospital de São João10 papers (2012–2021)Charlotte R. Grant · University College London9 papers (2012–2017)Eva Csizmadia · Lund University7 papers (2016–2023)Michael A. Heneghan · King's College London5 papers (2015–2021)Beth Holder · NIHR Imperial Biomedical Research Centre4 papers (2012–2015)Muhammed Yüksel · Koç University3 papers (2017–2021)Marta Vuerich · University of Ferrara3 papers (2020–2024)Yan Wu · Union Hospital3 papers (2017–2020)Jonathon J. Graham · Beth Israel Deaconess Medical Center3 papers (2017–2021)Linda Feldbrügge · Medizinische Hochschule Hannover3 papers (2017–2019)Z. Gordon Jiang · Shanghai Academy of Agricultural Sciences2 papers (2016–2019)Alan C. Moss · Action Against Medical Accidents2 papers (2014–2018) · 2 papers (2017–2020)Alan Bonder · Harvard University2 papers (2020–2023)Mark McPhail · Apple (Israel)2 papers (2021–2021) · 2 papers (2018–2020)